Anand Kumar Jain

Anand Kumar Jain

Auto-generated profile, based on publicly available information

Anand Kumar Jain

Department of Organ Transplant Anaesthesia and Critical Care, Mahatma Gandhi Medical College and Hospital, Jaipur, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
AJAshish Jain
Ashish Jain
RJRohit Jain
Rohit Jain
RKRajeev Kasliwal
Rajeev Kasliwal
PGPriyamvada Gupta
Priyamvada Gupta
AJAnand Jain
Anand Jain
RJRavi Jain
Ravi Jain
Purpose: End-organ damage in coronavirus disease-2019 (COVID-19) is linked to "cytokine storm" and excessive release of inflammatory mediators. Various novel therapies have been used in COVID-19 including urinary trypsin inhibitor therapy. This study explores the efficacy of ulinastatin in COVID-19. Materials and methods: We retrieved the medical records of patients admitted during one month and did a propensity score analysis to create matched treatment and control groups. We analyzed these groups and the outcomes were presented with appropriate statistics. Survival curve was prepared to compare the survival effect of ulinastatin therapy at the end of hospitalization, among both the groups. Results: A total of 736 patients were admitted, and after adjusting the data with propensity score matching, 55 cases were selected by the system. On the final outcome analysis, we found that intensive care unit (ICU) length of stay [median (interquartile range) days 3 (3.5-7.8) vs 2 (0-4); p-value 0.28] in control vs intervention groups, and in hospital mortality (odds ratio: 0.491, CI 95%: 0.099-2.44, p-value 0.435) were not statistically different among the groups. In survival plot analysis also, there was no statistical difference (p-value 0.414) among both the groups. Conclusion: In this retrospective study, we conclude that the final outcome of the ICU length of stay, and overall, in hospital mortality were not different among both the groups. Hence, adequately powered randomized control trials are urgently required to confirm any benefit of ulinastatin therapy in COVID-19 treatment.

1 April 2024 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
KGKashish Garg
Kashish Garg
AJAnand Kumar Jain
Anand Kumar Jain
GNGanesh Ramaji Nimje
Ganesh Ramaji Nimje
KKKamal Kajal
Kamal Kajal